These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 24233342

  • 1. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
    Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY.
    Cancer Immunol Immunother; 2014 Feb; 63(2):161-74. PubMed ID: 24233342
    [Abstract] [Full Text] [Related]

  • 2. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
    Tsang KY, Palena C, Gulley J, Arlen P, Schlom J.
    Clin Cancer Res; 2004 Mar 15; 10(6):2139-49. PubMed ID: 15041735
    [Abstract] [Full Text] [Related]

  • 3. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
    Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W.
    Blood; 1999 Jun 15; 93(12):4309-17. PubMed ID: 10361129
    [Abstract] [Full Text] [Related]

  • 4. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
    Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R.
    Int J Cancer; 2001 Feb 01; 91(3):385-92. PubMed ID: 11169964
    [Abstract] [Full Text] [Related]

  • 5. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM, Kinarsky L, Caffrey T, Hanisch FG, Sanderson S, Hollingsworth MA, Sherman S.
    Int Immunopharmacol; 2005 Feb 01; 5(2):315-30. PubMed ID: 15652762
    [Abstract] [Full Text] [Related]

  • 6. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
    Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF.
    Vaccine; 2000 Apr 03; 18(19):2059-71. PubMed ID: 10706970
    [Abstract] [Full Text] [Related]

  • 7. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
    Carmon L, El-Shami KM, Paz A, Pascolo S, Tzehoval E, Tirosh B, Koren R, Feldman M, Fridkin M, Lemonnier FA, Eisenbach L.
    Int J Cancer; 2000 Feb 01; 85(3):391-7. PubMed ID: 10652432
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
    Brooks N, Hsu J, Esparon S, Pouniotis D, Pietersz GA.
    Molecules; 2018 Sep 02; 23(9):. PubMed ID: 30200528
    [Abstract] [Full Text] [Related]

  • 9. The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.
    Mitchell MS, Lund TA, Sewell AK, Marincola FM, Paul E, Schroder K, Wilson DB, Kan-Mitchell J.
    Cancer Immunol Immunother; 2007 Mar 02; 56(3):287-301. PubMed ID: 16874487
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J.
    Cancer Res; 1997 Oct 15; 57(20):4570-7. PubMed ID: 9377571
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y.
    Cancer Res; 2002 Oct 15; 62(20):5835-44. PubMed ID: 12384546
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
    Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D.
    Int J Cancer; 2002 Mar 20; 98(3):409-14. PubMed ID: 11920592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.